Cite

HARVARD Citation

    Zhang, T. et al. (2020). A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer. Cancer. 126 (20), pp. 4485-4497. [Online]. 
  
Back to record